93-O17S-F changed size and zeta potential after mixing with tumor lysate and delivered model antigen to draining lymph nodes in vivo.
Protein/tumor-lysate capture experiments · Primary article Results, Fig. 5 and cited Supplementary Figs. S5-S6sales@dcchemicals.com
93-O17S
Formulation & Performance
Literature-reported formulation composition
| Component | Reported mass ratio (w/w) | Role |
|---|---|---|
| 93-O17S | 16 | Ionizable lipid |
| Cholesterol | 4 | Sterol |
| DOPE | 1 | Helper phospholipid |
| Reported ratio sum | 21 | Original ratio retained |
Formulation calculator unavailable. The source reports 93-O17S/Cholesterol/DOPE = 16/4/1 by weight, not mol%. A molar component-weight calculator would require a different input basis and is therefore not applied. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Literature-reported performance for the cited formulation
Literature-reported85%93-O17S-F/cGAMP-FluoPrimary article Methods, Cellular uptake of cGAMP
Literature-reported6.9-fold (RAW264.7) and 6.4-fold (DC2.4) versus PBS93-O17S-F/cGAMP; 4 h; n=6Primary article Results, Fig. 3C
Literature-reported>100-fold versus PBS93-O17S-F/cGAMP; 4 h; n=6Primary article Results, Fig. 3D
Literature-reported~1.4% without cGAMP and ~1.8% with cGAMPSpleen after prime-boost OVA vaccination; n=3Primary article Results, Fig. 4B
Literature-reported~60% without cGAMP and ~70% with cGAMPIn vivo cytotoxic T-cell assay; n=2Primary article Results, Fig. 4C
Literature-reported2/7 mice (28.6%) tumor-free by day 30DOX pretreatment + intratumoral 93-O17S-F/cGAMP on days 1 and 5Primary article Results, Fig. 6C-E
Selected 93-O17S-F experiments
| Experiment | Study condition | Reported result |
|---|---|---|
| cGAMP delivery | RAW264.7 and DC2.4; 4 h | Cytosolic distribution; 85% cGAMP-Fluo encapsulation |
| OVA vaccination | Prime/boost on days 1 and 14 | ~1.8% OVA-specific CD8+ T cells with cGAMP |
| Tumor therapy | DOX day 0; 93-O17S-F/cGAMP days 1 and 5 | 2/7 mice tumor-free by day 30 |
Primary article Figs. 3, 4 and 6.
Additional reported findings
93-O17S-F/cGAMP without DOX pretreatment produced only modest tumor inhibition; the strongest effect required prior DOX-induced antigen release.
B16F10 model · Primary article Results, Fig. 6Among mice that recovered from the primary tumor and were rechallenged, 71% were tumor-free 30 days after rechallenge.
Selected primary-tumor responders; n=7 rechallenge · Primary article Results, Fig. 6GLiterature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetChen J, et al. In situ cancer vaccination using lipidoid nanoparticles. Science Advances. 2021;7(19):eabf1244. DOI: 10.1126/sciadv.abf1244
The page distinguishes blank 93-O17S-F, OVA/cGAMP vaccination and DOX-combination tumor experiments; their results are not treated as interchangeable.
The page distinguishes blank 93-O17S-F, OVA/cGAMP vaccination and DOX-combination tumor experiments; their results are not treated as interchangeable.